The DOI matches its Crossref record.
1660TiP First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ABBV-969 and DXC-008 are dual-targeting PSMAxSTEAP1 ADCs carrying a TOPI inhibitor or tubulysin B analog payload, respectively.
“ABBV-969 and DXC-008 are dual-targeting PSMAxSTEAP1 ADCs carrying a TOPI inhibitor or tubulysin B analog payload, respectively; both are also currently undergoing phase I clinical trials in patients with prostate cancer (NCT06318273 and NCT06926283, respectively)120–122.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [120]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorted by citations
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01131-0 · Cited by 20
Metadata
- Authors
- Berger, R., Tolcher, A. W., Dorff, T. B., Okubo, S., Abraham, L. S., Reilly, R., Stevenson, C., Wang, S., Arnold, J., Mudd, S. R., Alaei, S., Hong, J., Quinn, D. I., Saad, F., & Powderly, J.
- Affiliations
- Tel Aviv University (IL)
- City Of Hope National Medical Center (US)
- AbbVie (United States) (US)
- Carolina BioOncology Institute (US)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2024-09
- Volume
- 35
- Pages
- S1000-S1001
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4402704908
- Cited by
- 8
- References
- 0
- Citations by year
- 2026: 5 · 2025: 3
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Funders
- Aptitude Health
- AbbVie
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- antibody-drug conjugates, metastatic castration-resistant prostate cancer, STEAP1, prostate-specific membrane antigen, topoisomerase I inhibitor, targeted cancer therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
